BioCentury | Feb 18, 2021
Management Tracks

Day One names York COO, CFO; plus moves at Coherus, Antios, ArsenalBio, Affinia, Artelo and more

...Cue Biopharma Inc. (NASDAQ:CUE) as SVP of clinical development. Levisetti previously served as CMO at DNAtrix Inc. Westlake...
BioCentury | Jan 12, 2021
Product Development

OX40L pipeline: Data Byte

...solid tumor and lymphoma patients. mRNA-2416 is also in a Phase II trial in ovarian cancer patients.DNAtrix Inc....
...4 OX40L (CD134L) – OX40 ligand Danielle Golovin KY1005 MRNA-2416 mRNA-2752 SL-279252, TAK-252 ISB 830 Kymab Group Ltd. Moderna Inc. Takeda Pharmaceutical Co. Ltd. AbbVie Inc. HiFiBiO Therapeutics DNAtrix Inc. Ichnos...
BioCentury | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

...officer at the U.S.-based Eisai Inc. subsidiary of Eisai Co. Ltd. (Tokyo:4523). Oncolytic virus company DNAtrix Inc....
...company is developing diagnostics and CRISPR-based gene therapies for eye diseases. BioCentury Staff Disarm Therapeutics Inc. Twist Bioscience Corp. DNAtrix Inc. Gamida...
BioCentury | Sep 13, 2019
Emerging Company Profile

Valo: adding tumor antigens to oncolytic viruses

...need to first verify if a peptide can trigger T cell responses. Valo partnered with DNAtrix Inc....
...Clinical status: Preclinical Founded: 2016 by Vincenzo Cerullo University collaborators: University of Helsinki Corporate partners: DNAtrix Inc....
...to coat adenovirus surfaces with peptides Companies and Institutions Mentioned Achilles Therapeutics Ltd., Stevenage, U.K DNAtrix Inc....
BioCentury | Dec 13, 2018
Company News

Management tracks: Ambys, Foghorn

...hired Imran Alibhai as its first CEO. He was an SVP and managing director at DNAtrix Inc....
BioCentury | Aug 22, 2016
Clinical News

DNX-2401: Phase II started

...IV Keytruda pembrolizumab once every 3 weeks in about 48 patients, including those with gliosarcomas. DNAtrix...
...Last October, the companies partnered to conduct the trial (see BioCentury, Oct. 19, 2015). DNAtrix Inc....
BioCentury | Aug 8, 2016
Clinical News

DNX-2401 regulatory update

...EMA granted PRIority MEdicines (PRIME) designation to DNX-2401 from DNAtrix to treat recurrent glioblastoma. The company...
...oncolytic adenovirus that uses arginine-glycine-aspartic acid (RGD)-binding integrins to enter and replicate in tumor cells. DNAtrix Inc....
BioCentury | Apr 14, 2016
Strategy

Next stop: Houston

...several companies including Kodiak Sciences Inc. , which was founded in the Bay Area, and DNAtrix Inc....
...Cambridge, Mass. Cancer Prevention Research Institute of Texas, Austin, Texas Dana-Farber Cancer Institute, Boston, Mass. DNAtrix Inc....
BioCentury | Feb 29, 2016
Product Development

Infectious enthusiasm

...to its work with Amgen. In 2015 Merck began a collaboration to combine Keytruda with DNAtrix...
...Another tack is using an oncolytic virus to deliver gene therapy directly to tumor cells. DNAtrix...
...you can do that," said Kaufman. Kaufman said one reason Merck chose to collaborate with DNAtrix...
BioCentury | Oct 19, 2015
Company News

Merck, DNAtrix deal

...The companies partnered to conduct a Phase II trial combining DNX-2401 from DNAtrix and melanoma drug...
...declined to provide financial terms or further details. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. DNAtrix Inc....
Items per page:
1 - 10 of 21
BioCentury | Feb 18, 2021
Management Tracks

Day One names York COO, CFO; plus moves at Coherus, Antios, ArsenalBio, Affinia, Artelo and more

...Cue Biopharma Inc. (NASDAQ:CUE) as SVP of clinical development. Levisetti previously served as CMO at DNAtrix Inc. Westlake...
BioCentury | Jan 12, 2021
Product Development

OX40L pipeline: Data Byte

...solid tumor and lymphoma patients. mRNA-2416 is also in a Phase II trial in ovarian cancer patients.DNAtrix Inc....
...4 OX40L (CD134L) – OX40 ligand Danielle Golovin KY1005 MRNA-2416 mRNA-2752 SL-279252, TAK-252 ISB 830 Kymab Group Ltd. Moderna Inc. Takeda Pharmaceutical Co. Ltd. AbbVie Inc. HiFiBiO Therapeutics DNAtrix Inc. Ichnos...
BioCentury | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

...officer at the U.S.-based Eisai Inc. subsidiary of Eisai Co. Ltd. (Tokyo:4523). Oncolytic virus company DNAtrix Inc....
...company is developing diagnostics and CRISPR-based gene therapies for eye diseases. BioCentury Staff Disarm Therapeutics Inc. Twist Bioscience Corp. DNAtrix Inc. Gamida...
BioCentury | Sep 13, 2019
Emerging Company Profile

Valo: adding tumor antigens to oncolytic viruses

...need to first verify if a peptide can trigger T cell responses. Valo partnered with DNAtrix Inc....
...Clinical status: Preclinical Founded: 2016 by Vincenzo Cerullo University collaborators: University of Helsinki Corporate partners: DNAtrix Inc....
...to coat adenovirus surfaces with peptides Companies and Institutions Mentioned Achilles Therapeutics Ltd., Stevenage, U.K DNAtrix Inc....
BioCentury | Dec 13, 2018
Company News

Management tracks: Ambys, Foghorn

...hired Imran Alibhai as its first CEO. He was an SVP and managing director at DNAtrix Inc....
BioCentury | Aug 22, 2016
Clinical News

DNX-2401: Phase II started

...IV Keytruda pembrolizumab once every 3 weeks in about 48 patients, including those with gliosarcomas. DNAtrix...
...Last October, the companies partnered to conduct the trial (see BioCentury, Oct. 19, 2015). DNAtrix Inc....
BioCentury | Aug 8, 2016
Clinical News

DNX-2401 regulatory update

...EMA granted PRIority MEdicines (PRIME) designation to DNX-2401 from DNAtrix to treat recurrent glioblastoma. The company...
...oncolytic adenovirus that uses arginine-glycine-aspartic acid (RGD)-binding integrins to enter and replicate in tumor cells. DNAtrix Inc....
BioCentury | Apr 14, 2016
Strategy

Next stop: Houston

...several companies including Kodiak Sciences Inc. , which was founded in the Bay Area, and DNAtrix Inc....
...Cambridge, Mass. Cancer Prevention Research Institute of Texas, Austin, Texas Dana-Farber Cancer Institute, Boston, Mass. DNAtrix Inc....
BioCentury | Feb 29, 2016
Product Development

Infectious enthusiasm

...to its work with Amgen. In 2015 Merck began a collaboration to combine Keytruda with DNAtrix...
...Another tack is using an oncolytic virus to deliver gene therapy directly to tumor cells. DNAtrix...
...you can do that," said Kaufman. Kaufman said one reason Merck chose to collaborate with DNAtrix...
BioCentury | Oct 19, 2015
Company News

Merck, DNAtrix deal

...The companies partnered to conduct a Phase II trial combining DNX-2401 from DNAtrix and melanoma drug...
...declined to provide financial terms or further details. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. DNAtrix Inc....
Items per page:
1 - 10 of 21